NewAmsterdam Pharma Company N.V. filed an amendment detailing the final terms of separation and advisory agreements with former Chief Operating Officer Douglas Kling, who resigned effective August 14, 2026 to become chief executive officer of another clinical-stage biotech company. Under a letter separation agreement with a subsidiary, Kling’s unvested stock options and restricted stock units as of the separation date are canceled, except for portions that vest solely based on continued service through May 14, 2027, which may continue to vest while he serves as an advisor. The agreement also includes confidentiality, non-disparagement, non-solicitation covenants, and a release of claims. A separate advisor agreement with another subsidiary provides that Kling will deliver transition and advisory services related to the PREVAIL clinical trial of obicetrapib and other programs for a $50,000 monthly service fee plus reimbursable expenses, through May 14, 2027 unless terminated earlier.
NewAmsterdam Pharma Co N.V. reported that Robert William Gunning, who serves as Vice President, Controller, filed an initial statement of beneficial ownership on Form 3. The filing lists no reportable equity transactions or holdings at this time.
NewAmsterdam Pharma Company N.V. appointed Robert W. Gunning, 55, as principal accounting officer effective August 10, 2026, succeeding Louise Kooij, whose departure effective August 31, 2026 had been previously announced. Gunning joined as Vice President, Controller on the same date, bringing prior senior finance and controller experience at several biopharmaceutical and biotechnology companies.
Under a July 24, 2026 offer letter with a wholly owned subsidiary, Gunning will receive a $375,000 annual base salary and be eligible for an annual performance bonus targeted at 30% of base salary, prorated for his first year and subject to board discretion. He will also be granted 3,200 restricted stock units and a stock option to purchase 14,000 ordinary shares under the 2024 Inducement Plan. The company states he has no disclosable related-party relationships or material interests in company transactions beyond standard indemnification arrangements.
FMR LLC and Abigail P. Johnson report a significant ownership position in PHARMA COMPANY NV. They beneficially own 10,339,663 shares of common stock, representing 8.8% of the class, based on information as of June 30, 2026.
FMR LLC has sole voting power over 10,329,760 shares and sole dispositive power over 10,339,663 shares, with no shared voting or dispositive power. Abigail P. Johnson is reported with sole dispositive power over the same 10,339,663 shares and no voting power, reflecting her position related to FMR LLC and its subsidiaries. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the outstanding common stock.
NewAmsterdam Pharma Company N.V. reported results for the quarter ended June 30, 2026 and highlighted regulatory and clinical developments. The Committee for Medicinal Products for Human Use issued a positive opinion recommending EU marketing authorization for obicetrapib (Ubeslo) and the obicetrapib/ezetimibe fixed-dose combination (Evlarco), with a European Commission decision expected later this year.
The company is running multiple Phase 3 programs, including the PREVAIL cardiovascular outcomes trial with over 9,500 patients enrolled and an interim analysis planned for the fourth quarter of 2026, the REMBRANDT imaging trial with 323 patients enrolled, and the RUBENS diabetes/metabolic syndrome trial targeting about 300 patients and topline data by year-end 2026. Cash, cash equivalents and marketable securities were $678.3 million at June 30, 2026. Revenue for the three months ended June 30, 2026 was $3.7 million versus $19.1 million a year earlier, reflecting lower contributions under the Menarini license and supply arrangements. R&D expenses rose to $41.7 million, SG&A expenses were $26.9 million, and net loss widened to $64.1 million compared with $17.4 million in the prior-year period.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company focused on CETP inhibitor obicetrapib for LDL-C lowering, reported Q2 2026 revenue of $3.7 million, down from $19.1 million as prior Menarini development contributions did not recur and revenue now reflects initial supply sales.
Research and development expenses rose to $41.7 million and selling, general and administrative expenses were $26.9 million, leading to a net loss of $64.1 million, or $0.52 per share; first-half net loss was $112.6 million. Cash, cash equivalents and marketable securities totaled $678.3 million at June 30 2026, with $69.8 million of operating cash outflows in the first half.
Operationally, the EMA’s CHMP issued a positive opinion recommending EU marketing authorization for obicetrapib monotherapy and fixed-dose combination with ezetimibe, with Menarini preparing potential launches in late 2026. The PREVAIL cardiovascular outcomes trial remains underway, with an interim analysis planned in Q4 2026 and a DSMB recommendation expected in Q1 2027.
NewAmsterdam Pharma Company N.V. reports that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe) to treat primary hypercholesterolemia, including heterozygous familial and non-familial or mixed dyslipidemia.
The recommendation is based on Phase 3 BROADWAY, BROOKLYN and TANDEM trials, which showed LDL-C reductions up to 40% with obicetrapib alone and approximately 50% in combination with ezetimibe versus placebo, with tolerability comparable to placebo. A European Commission decision, which could grant centralized EU marketing authorization, is expected in the second half of 2026.
Under a licensing agreement, Menarini holds exclusive European commercialization rights and is responsible for regulatory and commercial activities, while NewAmsterdam is eligible for tiered double-digit royalties and up to €833 million in additional milestones, and continues to run the over 9,500-patient PREVAIL cardiovascular outcomes trial.
NewAmsterdam Pharma Company N.V. announced that Chief Operating Officer Douglas Kling notified the company on July 16, 2026 that he will resign, with his departure effective August 14, 2026. He is leaving to become chief executive officer of another clinical-stage biotech company.
The company expects to enter into a separation agreement with Mr. Kling and an advisor agreement under which he would provide transition and advisory services for the PREVAIL clinical trial of obicetrapib and other clinical programs. Material terms of these agreements are expected to be disclosed later.
NewAmsterdam Pharma Co N.V. reports that Chief Accounting Officer Louise Frederika Kooij exercised stock options for 105000 ordinary shares on July 20, 2026, then sold 105000 shares in multiple transactions at weighted average prices of $29.9600, $31.0500 and $31.7100 per share, all under a Rule 10b5-1 trading plan adopted on February 23, 2026. Reported holdings include 22000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
NewAmsterdam Pharma Co N.V.’s Chief Accounting Officer Louise Frederika Kooij reported a combination of option exercises and share sales involving the company’s ordinary shares. On June 22, 2026, she exercised options to acquire a total of 40,000 ordinary shares through two transactions of 15,000 and 25,000 shares at exercise prices of $11.90 and $10.90 per share, respectively.
On the same date, she executed open-market sales totaling 40,000 ordinary shares in two transactions: 39,700 shares at $30.20 per share and 300 shares at a weighted average price of $30.73, with individual trade prices ranging from $29.73 to $30.72 per share. Following these transactions, her direct holdings continue to include 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.